A German pharma supply chain consortium formed by esteemed industry leaders Bayer, Boehringer Ingelheim, Frankfurt University of Applied Sciences, GEFCO, and others, announces its partnership with risk-based quality management pioneer Cyntegrity Germany GmbH.
The workshop at Robert J. Margolis Center for Health Policy at Duke University was to capture stakeholder input on the challenges, barriers, and enablers to implementation of Risk-Based Monitoring (RBM). The workshop also [...]
Cyntegrity project partner in digitization of pharmaceutical logistics: Frankfurt UAS' research project ensures greater transparency and security in the pharmaceutical supply chain.
Our key risk indicator infographic will give you a foundational understanding of KRIs, provide valuable examples of KRIs, and guide you towards getting started with your risk-based monitoring (RBM) program.
MCC Congratulates the 2018 Class of MCC Champions: "MCC bestows this special honor to those individuals who made significant contributions in 2018 in advancing the MCC mission to improve the efficiency, quality and effectiveness of clinical trials."
Zooming in on three key areas; analytics-driven feasibility, patient-centric enrolment planning and Risk-based Monitoring, SCOPE Europe professionally facilitated high level discussions between pharma industry leaders and decision makers.
Cyntegrity today announced the worldwide release of their Medical Device RACT, “MD-RACT”, the world’s first Risk Assessment and Categorization Tool for clinical investigations, that combines the best practices in Life Sciences with subject matter expertise in Medical Devices.
Many risks in clinical trials are therapy specific. Because of that, the currently available tools addressing those risks are now becoming therapy specific as well. The first therapy focused risk library Oncology RACT (OncoRACT) recently got available.